Pterygium is one of corneal-conjunctival pathologies that are frequently encountered by ophthalmologists. Its etiology, pathogenesis and treatment have been caused controversy for many years and remain as a problem, which is yet to be fully enlightened. The main treatment of pterygium is surgery. The most crucial postoperative problem is recurrence of the disease. Surgical methods have been sought for years to minimize recurrence with complementary treatment have been added to these methods including conjunctival autografting, bevacizumab and β-irradiation. No study was found to investigate additive use of bevacizumab and beta-radiation in postop or recurrent pterygium. Further phase 1 and phase 2 trials are needed to investigate the effectiveness of additive use of bevacizumab and beta-radiation in treatment of pterygium.
Key words: Bevacizumab, beta radiation, pterygium
|
